October 31, 2022 10:29 AM EDTUpdated 11:39 AM

J&J presses pause on a partner's PhI prostate cancer study, cutting off potential Erleada combo

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges